Cybin acquires dmt clinical study from entheon biomedical

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (cybin or the company), a biopharmaceutical company focused on progressing “psychedelics to therapeutics™”, today announced that, through its wholly-owned subsidiary cybin irl limited, it has entered into an agreement to acquire a phase 1 n,n-dimethyltryptamine (“dmt”) study (the “acquisition”) from entheon biomedical corp. (cse: enbi) (otcqb: entbf) (fse: 1xu1) (“entheon”) to accelerate the clinical development path for cyb00
CYBN Ratings Summary
CYBN Quant Ranking